Detail akcie Tharimmune Rg online

Business Summary: Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tharimmune Inc revenues was not reported. Net loss decreased 22% to $6.5M. Lower net loss reflects Pre-clinical biotechnology segment loss decrease of 24% to $6.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$7.75 to -$1.97.